Please Wait...

Rare Disease

Rare Disease New Developments

  • 0
  • 03 Jun
As a follow-up to my previous blog post on rare disease development in the pharmaceutical and biotech industry, here's a chart to show the increase in interest in applications since 1983, which was taken from the FDA website.
Read More

Growing Interest in Rare Disease for Pharma and Biotech Industry

  • 0
  • 01 Jun
At BioClinica, we are involved in a number of rare disease studies. This is a growing area of development for the pharmaceutical and biotech industry. FDA’s office of Orphan Product Development reports that they saw a record 323 orphan drug designation requests come through the door in 2010. It's unclear why – one reason could be OOPD's outreach efforts. Rare diseases are classified as those that affect fewer than 200,000 in the United States and less than 5 in 10,000 in Europe. It is estimated that in the United States, 47% of rare disorders affect fewer than 25,000 people. Because patient populations for rare diseases are so small, big pharmaceutical companies historically have had little financial incentive to invest in drug development for these diseases.
Read More

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Bioclinica is organized into three business segments so that we can provide expert service and multifaceted technologies. Our Medical Imaging & Biomarkers segment includes an Imaging Core Lab, a Cardiovascular Safety division, and a Molecular Marker Laboratory. Our eHealth segment comprises eClinical Solutions, Randomization & Trial Supply Management, Safety & Regulatory Solutions, and Financial Lifecycle Solutions. Under the Global Clinical Research segment, we offer a network of research sites, patient recruitment, and a Post-Approval Research division.

RT @eClinical_Jen: FREE on-demand webinars from @bioclinica on EDC, Imaging, RBM, and Clinical Trial Management. Tell them I sent you! http…
bioclinica (11 hours ago)
Excited to host NJ Lt. Gov. Kim Guadagno, clients, partners 9/28 in Princeton! In the area? Join us ! RSVP… https://t.co/PrfyxvasGb
bioclinica (Yesterday)
Be sure to follow #ThankAScientist all week to thank researchers for the work they do! https://t.co/Sfi9mmHbSk… https://t.co/y9ZhBXsIzu
bioclinica (2 days ago)
Cardiovascular imaging use is growing in non-cardiovascular areas #ClinicalTrials. See where in Tim Crowe's blog… https://t.co/dYjPBC0Wtn
bioclinica (2 days ago)
RT @Xtalks: Cardiovascular Safety in #Biopharmaceutical Product Development - From QT Prolongation and Beyond @bioclinica https://t.co/mCk1…
bioclinica (2 days ago)
RT @Xtalks: How Innovations in Data Visualization Are Accelerating Data Cleaning and Improving Quality @bioclinica https://t.co/vfLU8pS9Rd
bioclinica (2 days ago)

Latest Blogs: